Combination therapy for advanced malignant melanoma with BCNU, Pseudomonas vaccine, and heparin

R. D. Snyder, G. N. Hortobagyi, G. P. Bodey, J. U. Gutterman, Evan M Hersh

Research output: Contribution to journalArticle

Abstract

A study was undertaken to investigate the addition of heparin and Pseudomonas vaccine to BCNU in the treatment of patients with progressive malignant melanoma refractory to front-line therapeutic regimens containing DTIC. Out of 27 evaluable patients, there was one partial remission (4%), and an additional ten patients (41%) had at least stable disease with a median survival time of 39 weeks compared to 15 weeks for those with progressive disease. The therapy was well tolerated. A schedule of Pseudomonas vaccine that seemed to be tolerated has been established.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalJournal of Surgical Oncology
Volume16
Issue number1
DOIs
StatePublished - 1981
Externally publishedYes

Fingerprint

Pseudomonas Vaccines
Carmustine
Heparin
Melanoma
Dacarbazine
Appointments and Schedules
Therapeutics
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Combination therapy for advanced malignant melanoma with BCNU, Pseudomonas vaccine, and heparin. / Snyder, R. D.; Hortobagyi, G. N.; Bodey, G. P.; Gutterman, J. U.; Hersh, Evan M.

In: Journal of Surgical Oncology, Vol. 16, No. 1, 1981, p. 87-92.

Research output: Contribution to journalArticle

Snyder, R. D. ; Hortobagyi, G. N. ; Bodey, G. P. ; Gutterman, J. U. ; Hersh, Evan M. / Combination therapy for advanced malignant melanoma with BCNU, Pseudomonas vaccine, and heparin. In: Journal of Surgical Oncology. 1981 ; Vol. 16, No. 1. pp. 87-92.
@article{916d2ce623fd43f5b994aa38b1a55e38,
title = "Combination therapy for advanced malignant melanoma with BCNU, Pseudomonas vaccine, and heparin",
abstract = "A study was undertaken to investigate the addition of heparin and Pseudomonas vaccine to BCNU in the treatment of patients with progressive malignant melanoma refractory to front-line therapeutic regimens containing DTIC. Out of 27 evaluable patients, there was one partial remission (4{\%}), and an additional ten patients (41{\%}) had at least stable disease with a median survival time of 39 weeks compared to 15 weeks for those with progressive disease. The therapy was well tolerated. A schedule of Pseudomonas vaccine that seemed to be tolerated has been established.",
author = "Snyder, {R. D.} and Hortobagyi, {G. N.} and Bodey, {G. P.} and Gutterman, {J. U.} and Hersh, {Evan M}",
year = "1981",
doi = "10.1002/jso.2930160113",
language = "English (US)",
volume = "16",
pages = "87--92",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Combination therapy for advanced malignant melanoma with BCNU, Pseudomonas vaccine, and heparin

AU - Snyder, R. D.

AU - Hortobagyi, G. N.

AU - Bodey, G. P.

AU - Gutterman, J. U.

AU - Hersh, Evan M

PY - 1981

Y1 - 1981

N2 - A study was undertaken to investigate the addition of heparin and Pseudomonas vaccine to BCNU in the treatment of patients with progressive malignant melanoma refractory to front-line therapeutic regimens containing DTIC. Out of 27 evaluable patients, there was one partial remission (4%), and an additional ten patients (41%) had at least stable disease with a median survival time of 39 weeks compared to 15 weeks for those with progressive disease. The therapy was well tolerated. A schedule of Pseudomonas vaccine that seemed to be tolerated has been established.

AB - A study was undertaken to investigate the addition of heparin and Pseudomonas vaccine to BCNU in the treatment of patients with progressive malignant melanoma refractory to front-line therapeutic regimens containing DTIC. Out of 27 evaluable patients, there was one partial remission (4%), and an additional ten patients (41%) had at least stable disease with a median survival time of 39 weeks compared to 15 weeks for those with progressive disease. The therapy was well tolerated. A schedule of Pseudomonas vaccine that seemed to be tolerated has been established.

UR - http://www.scopus.com/inward/record.url?scp=0019366822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019366822&partnerID=8YFLogxK

U2 - 10.1002/jso.2930160113

DO - 10.1002/jso.2930160113

M3 - Article

C2 - 7464150

AN - SCOPUS:0019366822

VL - 16

SP - 87

EP - 92

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -